ALLRAllarity Therapeutics, Inc.

Nasdaq allarity.com


$ 0.15 $ 0.00 (1.83 %)    

Tuesday, 13-Aug-2024 13:08:01 EDT
QQQ $ 461.76 $ 7.65 (1.68 %)
DIA $ 397.37 $ 2.30 (0.58 %)
SPY $ 541.17 $ 5.09 (0.95 %)
TLT $ 97.11 $ -0.11 (-0.11 %)
GLD $ 228.01 $ 0.15 (0.07 %)
$ 0.1473
$ 0.15
$ 0.15 x 300
$ 0.15 x 300
$ 0.15 - $ 0.15
$ 0.14 - $ 43.60
762,594
na
6.24M
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-08-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-13-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 10-07-2022 06-30-2022 10-Q
10 05-27-2022 03-31-2022 10-Q
11 05-16-2022 09-30-2021 10-Q
12 05-16-2022 12-31-2021 10-K
13 11-23-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 allarity-therapeutics-hit-by-sec-notice-related-disclosures-of-once-lead-cancer-program

Allarity Therapeutics receives a Wells Notice from the SEC regarding disclosures about their FDA meetings for the New Drug Appl...

 allarity-received-a-wells-notice-from-sec-relating-to-its-disclosures-regarding-meetings-with-the-fda-regarding-nda-for-dovitinib-or-dovitinib-drp-which-was-submitted-in-2021-allaritys-three-former-officers-have-received-the-notice

Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfull...

 sec-issues-wells-notice-to-allarity-therapeutics-and-former-officers-over-2021-fda-nda-submission

On July 19, 2024, Allarity Therapeutics, Inc. (the “Company”) received a “Wells Notice” from the Staff of the U.S. Securities a...

 allarity-granted-hearing-before-nasdaq-panel-to-present-plan-of-regaining-compliance

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutica...

 allarity-therapeutics-dual-parptankyrase-inhibitor-stenoparib-to-show-extended-clinical-benefit-in-advanced-ovarian-cancer

Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. ("Allarity"...

 why-allarity-therapeutics-allr-stock-is-getting-hammered

Allarity Therapeutics shares are trading lower by 27.6% during Monday's session. The company announced that it received a n...

 reported-earlier-allarity-therapeutics-faces-nasdaq-delisting-for-stock-price-below-1

On June 18, 2024, Allarity Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (t...

 allarity-therapeutics-reports-clear-clinical-benefits-from-phase-2-trial-improves-cash-balance-of-14m-and-equity-balances-of-15m-withdraws-from-s-1

- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All N...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION